Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glycopeptide derivatives.

A Malabarba1, R Ciabatti

  • 1Biosearch Italia S.p.A., Via R. Lepetit, Gerenzano, 34 - 21040, Italy. amalabarba@biosearch.it

Current Medicinal Chemistry
|September 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 N-alkylated at the aminoglucuronyl moiety.

The Journal of antibiotics·1998
Same author

Mono and double modified teicoplanin aglycon derivatives on the amino acid no. 7; structure-activity relationship.

The Journal of antibiotics·1998
Same author

Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects.

Farmaco (Societa chimica italiana : 1989)·1997
Same author

[Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity].

Bioorganicheskaia khimiia·1997
Same author

Antimicrobial activities of chemically modified thiazolyl peptide antibiotic MDL 62,879 (GE2270A).

The Journal of antibiotics·1997
Same author

Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections.

Journal of medicinal chemistry·1997

New glycopeptides are being developed to combat rising antibiotic resistance in bacteria like VanA enterococci and GISA. These second-generation drugs show promise against difficult-to-treat infections, offering hope for improved therapeutic options.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Increasing resistance to glycopeptide antibiotics (e.g., vancomycin) in enterococci and Staphylococcus aureus poses a significant clinical challenge.
  • The emergence of VanA strains and vancomycin-intermediate Staphylococcus aureus (GISA) necessitates the development of novel therapeutic agents.
  • Existing treatment options are limited, particularly for infections caused by multidrug-resistant Gram-positive bacteria.

Purpose of the Study:

  • To review the development of second-generation glycopeptides with enhanced activity against resistant bacteria.
  • To discuss novel chemical modifications aimed at overcoming glycopeptide resistance mechanisms.
  • To highlight compounds currently in clinical trials for treating resistant infections.

Main Methods:

Related Experiment Videos

  • Chemical modification of existing glycopeptide structures (vancomycin, teicoplanin).
  • Development of second-generation compounds like LY333328 and BI 397.
  • Exploration of modifications to the heptapeptide core and sugar moieties.
  • Synthesis of glycopeptide dimers and vancomycin derivatives.

Main Results:

  • Second-generation glycopeptides LY333328 and BI 397 demonstrate promising activity against VanA enterococci, GISA, and penicillin-resistant pneumococci.
  • Chemical modifications targeting the heptapeptide core and D-Ala-D-Ala/D-Ala-D-Lactate binding interactions show potential.
  • Ongoing clinical trials are evaluating the efficacy and safety of these novel glycopeptides.

Conclusions:

  • There is an urgent need for new glycopeptides to address the growing threat of antibiotic resistance.
  • Chemical innovation in glycopeptide structure is yielding promising drug candidates.
  • Further research and clinical evaluation are crucial for the successful deployment of these next-generation antibiotics.